scholarly journals Applications liposome in cancer drug delivery and treatment: A review

2019 ◽  
Vol 7 (1) ◽  
pp. 62-65 ◽  
Author(s):  
Dr.Nandish Pathak ◽  
Dr. Pratim Pathak
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Cells ◽  
Radiation Treatment ◽  
Pegylated Liposomal Doxorubicin ◽  
Malignant Cell ◽  
The Body ◽  
Phospholipid Bilayer ◽  
Cancer Drug ◽  
Cancer Drug Delivery

In the world the biggest challenges to cure the cancer because of the abnormal cancer cells growth in the human body which is near to uncontrollable. These cells known as the malignant cell because it produced the cancer.  There are several treatments for cancer such as surgery, chemotherapy, radiation treatment etc. however such treatments have major side effects like normal cell got killed, loss of hair, the surgery person skill also in consideration and high chances of reoccurrences. Due to such side effects these treatment drugs are less popular. To reduces such side effects the liposomal based treatments are the most preferable solution.  The liposomes are the phospholipid bilayer vesicles and it has high encapsulation capacity. Therefore, liposomal based treatment plays significant role in the cancer treatment with less toxicity and other many advantages. The liposomal based drug pegylated liposomal doxorubicin and daunorubicin have advanced effect in the body. Furthermore, the development of the liposomes as immunoliposomes, ligand targeted and molecular targeting. This review explores the liposomal based drug delivery system, its advance effect on the cancer cells and clinically approve liposomes formulations.

scholarly journals Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Sonia Iranpour ◽  
Ahmad Reza Bahrami ◽  
Sirous Nekooei ◽  
Amir Sh. Saljooghi ◽  
Maryam M. Matin
Keyword(s):  
Colorectal Cancer ◽  
Drug Delivery ◽  
Side Effects ◽  
Mesoporous Silica ◽  
Cancer Drug ◽  
Delivery Performance ◽  
Anti Cancer ◽  
Cancer Drug Delivery ◽  
Magnetic Mesoporous Silica ◽  
Ht 29

Abstract Background Improving anti-cancer drug delivery performance can be achieved through designing smart and targeted drug delivery systems (DDSs). For this aim, it is important to evaluate overexpressed biomarkers in the tumor microenvironment (TME) for optimizing DDSs. Materials and methods Herein, we designed a novel DDS based on magnetic mesoporous silica core–shell nanoparticles (SPION@MSNs) in which release of doxorubicin (DOX) at the physiologic pH was blocked with gold gatekeepers. In this platform, we conjugated heterofunctional polyethylene glycol (PEG) onto the outer surface of nanocarriers to increase their biocompatibility. At the final stage, an epithelial cell adhesion molecule (EpCAM) aptamer as an active targeting moiety was covalently attached (Apt-PEG-Au@NPs-DOX) for selective drug delivery to colorectal cancer (CRC) cells. The physicochemical properties of non-targeted and targeted nanocarriers were fully characterized. The anti-cancer activity, cellular internalization, and then the cell death mechanism of prepared nanocarriers were determined and compared in vitro. Finally, tumor inhibitory effects, biodistribution and possible side effects of the nanocarriers were evaluated in immunocompromised C57BL/6 mice bearing human HT-29 tumors. Results Nanocarriers were successfully synthesized with a mean final size diameter of 58.22 ± 8.54 nm. Higher cytotoxicity and cellular uptake of targeted nanocarriers were shown in the EpCAM-positive HT-29 cells as compared to the EpCAM-negative CHO cells, indicating the efficacy of aptamer as a targeting agent. In vivo results in a humanized mouse model showed that targeted nanocarriers could effectively increase DOX accumulation in the tumor site, inhibit tumor growth, and reduce the adverse side effects. Conclusion These results suggest that corporation of a magnetic core, gold gatekeeper, PEG and aptamer can strongly improve drug delivery performance and provide a theranostic DDS for efficient CRC therapy. Graphic abstract

Nanotherapeutics and nanotheragnostics for cancers: properties, pharmacokinetics, biopharmaceutics, and biosafety

2021 ◽  
Vol 27 ◽  
Author(s):  
Margreet Morsink ◽  
Lucia Parente ◽  
Fernanda Silva ◽  
Alexandra Abrantes ◽  
Ana Ramos ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Quality Control ◽  
Side Effects ◽  
Chronic Diseases ◽  
Patient Compliance ◽  
Therapeutic Agents ◽  
Cancer Drug ◽  
High Quality ◽  
Specific Targeting ◽  
Cancer Drug Delivery

: With the worldwide increasing rate of chronic diseases, such as cancer, the development of novel techniques to improve the efficacy of therapeutic agents is highly demanded. Nanoparticles are especially well suited to encapsulate drugs and other therapeutic agents, bringing additional advantages, such as less frequent dosage requirements, reduced side effects due to specific targeting, and therefore increased patient compliance. However, with the increasing use of nanoparticles and their recent launch on the pharmaceutical market it is important to achieve high quality control of these advanced systems. In this review, we discuss the properties of different nanoparticles, the pharmacokinetics, the biosafety issues of concern, and conclude with novel nanotherapeutics and nanotheragnostics for cancer drug delivery.

scholarly journals Surface modified receptor mediated delivery systems for site specific treatment of cancer

2021 ◽  
Vol 9 (1) ◽  
pp. 1-7
Author(s):  
Fenil Vanapariya ◽  
Miteshkumar Malviya ◽  
Shiroya Milankumar Nathabhai
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Drug Carrier ◽  
Specific Treatment ◽  
The Body ◽  
Cancer Drug ◽  
Specific Drug ◽  
Formulation Development ◽  
Site Specific ◽  
Surface Modified

The treatment of the cancer has many challenges now a days due to side effects of the treatment. However, in the modern formulation development the concept of the site specific drug delivery for disease treatment in the body is considering as continuous challenges. Observing the challenges in convectional technique site specific drug delivery system has good potential to reduce adverse side effects, efficiently improve the human body health with very low toxicity. This review article elaborates the current challenges and prospective of surface modified drug carrier systems for delivery of protein for site-specific treatment of cancer and anti-cancer drug.

scholarly journals Docetaxel-Loaded Disulfide Cross-Linked Nanoparticles Derived from Thiolated Sodium Alginate for Colon Cancer Drug Delivery

Pharmaceutics ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 38 ◽  
Author(s):  
Hock Ing Chiu ◽  
Asila Dinie Ayub ◽  
Siti Nur Aishah Mat Yusuf ◽  
Noorfatimah Yahaya ◽  
Erazuliana Abd Kadir ◽  
...  
Keyword(s):  
Electron Microscopy ◽  
Drug Delivery ◽  
Colon Cancer ◽  
Drug Release ◽  
Cancer Cells ◽  
Sodium Alginate ◽  
Cancer Drug ◽  
Colon Cancer Cells ◽  
Cancer Drug Delivery ◽  
Ht 29

In this study, fluorescein-labelled wheat germ agglutinin (fWGA)-conjugated disulfide cross-linked sodium alginate nanoparticles were developed to specifically target docetaxel (DTX) to colon cancer cells. Different amounts of 3-mercaptopropionic acid (MPA) were covalently attached to sodium alginate to form thiolated sodium alginate (MPA1–5). These polymers were then self-assembled and air-oxidised to form disulfide cross-linked nanoparticles (MP1–5) under sonication. DTX was successfully loaded into the resulting MP1–5 to form DTX-loaded nanoparticles (DMP1–5). DMP2 had the highest loading efficiency (17.8%), thus was chosen for fWGA surface conjugation to form fWGA-conjugated nanoparticles (fDMP2) with a conjugation efficiency of 14.1%. Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) analyses showed spherical nanoparticles, and an in vitro drug release study recorded a cumulative drug release of 48.6%. Dynamic light scattering (DLS) analysis revealed a mean diameter (MD) of 289 nm with a polydispersity index (PDI) of 0.3 and a zeta potential of −2.2 mV for fDMP2. HT-29 human colon cancer cells treated with fDMP2 showed lower viability than that of L929 mouse fibroblast cells. These results indicate that fDMP2 was efficiently taken up by HT-29 cells (29.9%). Fluorescence and confocal imaging analyses also showed possible internalisation of nanoparticles by HT-29 cells. In conclusion, fDMP2 shows promise as a DTX carrier for colon cancer drug delivery.

Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade

2020 ◽  
Vol 27 ◽  
Author(s):  
Muhammad Sohail ◽  
Wenna Guo ◽  
Zhiyong Li ◽  
Hui Xu ◽  
Feng Zhao ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Therapy ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Research Progress ◽  
Cancer Drug ◽  
Conventional Chemotherapy ◽  
Anti Cancer ◽  
Cancer Drug Delivery

: In recent years, due to the shortcomings of conventional chemotherapy, such as poor bioavailability, low treatment index and unclear side effects, the focus of cancer research has shifted to new nanocarriers of chemotherapeutic drugs. By using biodegradable materials, nanocarriers generally have the advantages of good biocompatibility, low side effects, targeting, controlled release profile, and improved efficacy. And more to the point, nanocarrier based anti-cancer drug delivery systems clearly show the potential to overcome the problems associated with conventional chemotherapy. In order to promote the deepening of research and development in this field, we herein summarized and analyzed various nanocarrier based drug delivery systems for cancer therapy, including the concepts, types, characteristics and preparation methods. The active and passive targeting mechanisms of cancer therapy were also included, along with a brief introduction of the research progress of nanocarriers used for anti-cancer drug delivery in the past decade.

scholarly journals Nanotechnology in Cancer Drug Delivery and Selective Targeting

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Kumar Bishwajit Sutradhar ◽  
Md. Lutful Amin
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Treatment ◽  
Direct Access ◽  
Cancer Drug ◽  
Proliferating Cells ◽  
Selective Targeting ◽  
Traditional Drug ◽  
Cancer Drug Delivery ◽  
Cancerous Cells

Nanoparticles are rapidly being developed and trialed to overcome several limitations of traditional drug delivery systems and are coming up as a distinct therapeutics for cancer treatment. Conventional chemotherapeutics possess some serious side effects including damage of the immune system and other organs with rapidly proliferating cells due to nonspecific targeting, lack of solubility, and inability to enter the core of the tumors resulting in impaired treatment with reduced dose and with low survival rate. Nanotechnology has provided the opportunity to get direct access of the cancerous cells selectively with increased drug localization and cellular uptake. Nanoparticles can be programmed for recognizing the cancerous cells and giving selective and accurate drug delivery avoiding interaction with the healthy cells. This review focuses on cell recognizing ability of nanoparticles by various strategies having unique identifying properties that distinguish them from previous anticancer therapies. It also discusses specific drug delivery by nanoparticles inside the cells illustrating many successful researches and how nanoparticles remove the side effects of conventional therapies with tailored cancer treatment.

Targeted pancreatic cancer drug-delivery utilizing sigma-2 ligand/receptor internalization is energy-dependent.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 331-331
Author(s):  
Linda X Jin ◽  
Suwanna Vangveravong ◽  
Darren R Cullinan ◽  
Peter S. Goedegebuure ◽  
Andrew J Loza ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Cancer Drug ◽  
Receptor Ligands ◽  
Ligand Interaction ◽  
Receptor Ligand ◽  
Pancreatic Cancer Cells ◽  
Cancer Drug Delivery ◽  
Energy Dependent

331 Background: Pancreatic cancer is a devastating disease that is poorly responsive to traditional systemic therapies. Cancer-selective drug delivery can improve survival and reduce systemic toxicities. We have developed a pancreatic cancer drug delivery platform based on sigma-2 receptor ligands conjugated to small molecule drug cargos, which improves delivery and efficacy through efficient drug internalization. However, the mechanism of drug internalization via the sigma-2 receptor/ligand interaction remains unclear. Methods: Uptake of fluorescently conjugated sigma-2 ligand SW120 was studied in ASPC-1 human pancreatic cancer cells. Uptake was measured at 37C, 4C, after competitive inhibition with sigma-2 ligand SW43, and after pretreatment with Pitstop 2 (Abcam), an inhibiter of clathrin-mediated endocytosis. Uptake was visualized using live-cell imaging using A1Rsi confocal laser scanning microscope (Nikon). Image analysis was performed using FIJI (NIH) and Matlab (Mathworks). Results: SW120 (10 nM) was rapidly internalized into ASPC-1 cells at 37C with maximal fluorescence at 12 minutes. As a negative control, incubation of ASPC-1 cells with the unconjugated flourophore NBD Cl demonstrated no uptake after 15 minutes, indicating that uptake of SW120 depends on the specific sigma-2 receptor/ligand interaction. Fluorescence at 15 minutes was reduced by 85% in ASPC-1 cells incubated at 4C, indicating uptake of SW120 into cells is an energy dependent process. Pretreatment of cells with Pitstop 2 decreased total flourescence at 15 minutes by 76%, suggesting an important role of clathrin-mediated endocytosis in sigma-2 receptor uptake, while pretreatment with competitive inhibitor SW43 reduced uptake by 84%, suggesting that sigma-2 ligands are internalized via a specific receptor capable of saturation. Conclusions: Sigma-2 receptor ligands are rapidly internalized into pancreatic cancer cells via a specific, targetable, energy-dependent pathway that appears to rely on clathrin-mediated endocytosis. Further understanding of sigma-2 mediated drug internalization can help optimize targeted drug development and delivery for pancreatic cancer patients.

scholarly journals Polymeric Micelles for Cancer Drug Delivery and Targeting

2021 ◽  
Vol 290 ◽  
pp. 01014
Author(s):  
Yuyan Wang
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Polymeric Micelles ◽  
Cancer Drug ◽  
Therapeutic Approaches ◽  
Tumor Microenvironments ◽  
Chemical Treatments ◽  
The Past ◽  
Discharge Profile ◽  
Cancer Drug Delivery

Over the past years, the emergence of various therapeutic approaches has attracted so much consideration, but chemotherapy remains the most effective way in experimental practice. However, due to obstacles and difficulties, there is a limitation for the additional clinical presentation of the outdated chemical treatments such as paclitaxel and doxorubicin. Some of the barriers are severe side effects, profound cytotoxicity, and low therapeutic efficacy. Drug delivery systems (DDS) such as polymeric micelles have been technologically advanced over the recent decades to advance the treatment efficacy and lessen the side effects incurred. The polymeric micelles self-assembled from amphiphilic polymers serve to sum up hydrophobic treatments in the core and regulate the discharge profile of the drugs through response towards stimuli of the tumor microenvironments, which in this case are pH, temperature, light, and reduction.

Sign in / Sign up

Export Citation Format

Share Document